Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.

Nature medicine·2022
Same author

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.

Blood·2022
Same author

Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.

American journal of hematology·2022
Same author

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.

Blood advances·2022
Same author

The use of ICU resources in CAR-T cell recipients: a hospital-wide study.

Annals of intensive care·2022
Same author

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.

Blood advances·2022
Same journal

Incidence of Induction Toxicities in Childhood Acute Lymphoblastic Leukaemia in Ghana.

Advances in hematology·2026
Same journal

Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study.

Advances in hematology·2026
Same journal

The Natural Coagulation Inhibitors, Inflammation, and Thrombotic Risk in Sickle Cell Patients in Cameroon: An Analytical Cross-Sectional Study.

Advances in hematology·2026
Same journal

Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings.

Advances in hematology·2026
Same journal

Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns.

Advances in hematology·2025
Same journal

Positive Indirect Antiglobulin Test in Adult Patients With Primary Warm Autoimmune Hemolytic Anemia: Clinical Significance and Prognostic Effect on Response to Corticosteroids.

Advances in hematology·2025
See all related articles

Related Experiment Videos

Lenalidomide in diffuse large B-cell lymphoma.

Catherine Thieblemont1, Marie-Hélène Delfau-Larue, Bertrand Coiffier

  • 1Hematology and Oncology Department, Hôpital Saint-Louis, AP-HP and IUH, INSERM U728, University Paris VII, 75010 Paris, France.

Advances in Hematology
|December 20, 2012
PubMed
Summary
This summary is machine-generated.

New immunomodulatory drugs like lenalidomide show promise for treating diffuse large B-cell lymphoma (DLBCL), a common non-Hodgkin

Related Experiment Videos

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin's lymphoma (NHL) in adults.
  • While immunochemotherapy has improved outcomes, novel therapeutic strategies are essential for better survival rates.
  • Lenalidomide, an immunomodulatory drug, offers pleiotropic mechanisms that may complement existing treatments.

Purpose of the Study:

  • To explore the biological rationale for using lenalidomide in DLBCL treatment.
  • To review recent advances in DLBCL pathophysiology and their therapeutic implications.
  • To summarize current therapeutic results of lenalidomide in relapsed/refractory and first-line DLBCL settings.

Main Methods:

  • Literature review of recent clinical trials and scientific meetings.
  • Analysis of lenalidomide's mechanisms of action in relation to DLBCL.
  • Synthesis of data on lenalidomide's efficacy in various DLBCL treatment scenarios.

Main Results:

  • Lenalidomide's immunomodulatory properties present a strong biological basis for its use in DLBCL.
  • Emerging data suggest lenalidomide's potential benefit in both relapsed/refractory and first-line DLBCL treatment.
  • Further investigation into lenalidomide-based regimens is warranted.

Conclusions:

  • Lenalidomide represents a promising therapeutic option for DLBCL.
  • Its integration into treatment protocols could improve patient outcomes.
  • Continued research is crucial to optimize its role in DLBCL management.